益母草注射液联合缩宫素预防产后出血的临床疗效与机制研究
本研究基于中国西南地区最大高危妊娠转诊中心的电子健康记录数据库(51,312例妊娠),结合Meta分析、动物实验和多种分子生物学方法,探讨益母草注射液联合缩宫素预防产后出血的临床疗效及机制。结果显示,联合用药较单用缩宫素可减少产后2小时和24小时出血量,降低产后出血风险约一半,其协同机制与激活MAPK信号通路、上调OXTR和Cx43表达有关。
要点
- 益母草注射液联合缩宫素可减少剖宫产产后2小时和24小时出血量。
- 联合方案降低产后出血风险(RR=0.49,95%CI 0.41–0.59)。
- 协同机制涉及MAPK信号通路激活及MEK1直接结合。
核心结论
- 益母草注射液联合缩宫素预防产后出血的疗效优于单用缩宫素。
- 其协同机制与激活MAPK信号通路、增强子宫收缩有关。
研究设计与样本
- 研究整合了真实世界数据、Meta分析和动物验证。
- 真实世界数据来自中国西南地区最大高危妊娠转诊中心的电子健康记录数据库,共纳入51,312例妊娠。
- 动物实验采用米非司酮和米索前列醇建立产后出血大鼠模型。
- 机制研究整合了网络药理学、代谢组学、免疫荧光、免疫组化、Western blot、分子对接、分子动力学模拟和表面等离子共振分析。
主要发现
- 在51,312例妊娠中,88.71%的剖宫产分娩使用了益母草注射液联合缩宫素预防产后出血。
- 与单用缩宫素相比,联合用药减少产后2小时出血量(WMD=-40.95,95%CI -58.04至-23.86)。
- 联合用药减少产后24小时出血量(WMD=-54.80,95%CI -72.09至-37.51)。
- 联合用药降低产后出血风险约一半(RR=0.49,95%CI 0.41至0.59)。
- 在大鼠模型中,联合治疗进一步减少产后出血量、缩短出血时间、改善子宫组织病理学,并上调OXTR和Cx43表达。
临床怎么用
- 对于剖宫产产后出血预防,可考虑益母草注射液联合缩宫素方案。
- 联合方案可能减少产后2小时和24小时出血量及产后出血风险。
局限性
- 真实世界数据来自单一中心,可能存在选择偏倚。
- 动物模型与人体存在种属差异,机制发现需进一步临床验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Postpartum hemorrhage (PPH) remains a leading cause of maternal mortality, while Chinese Motherwort (Leonurus japonicus Houtt.), known as "JingChanLiangYao", has been used to prevent PPH in traditional Chinese obstetric and gynecological practices for thousands of years. As a modern purified Chinese herbal preparation, motherwort injection is frequently administered alongside the international first-line treatment of oxytocin in clinical practice. However, the clinical efficacy and mechanism of this combined regimen in PPH prevention have not yet been fully elucidated. PURPOSE: To evaluate the clinical efficacy of motherwort injection in combination with oxytocin for enhanced PPH prevention and elucidate its underlying mechanisms. STUDY DESIGN: This study employed an integrative approach using real-world data, meta-analysis and animal validation. METHODS: This study utilized an electronic health record database from the largest referral center for high-risk pregnancies in southwest China to explore uterotonic treatment patterns in cesarean sections, with therapeutic efficacy validated though meta-analysis. Active compounds of motherwort injection were characterized using UPLC-HRMS. A PPH rat model was established using mifepristone and misoprostol, followed by histopathological analysis to evaluate the therapeutic efficacy of motherwort injection. Mechanistic investigations were further conducted by integrating network pharmacology, metabolomics, immunofluorescence, immunohistochemistry, Western blot, molecular docking, molecular dynamics simulation, and surface plasmon resonance (SPR) analysis to elucidate the potential mechanisms underlying the synergistic effects of motherwort injection combined with oxytocin in PPH prevention. RESULTS: We found 88.71 % deliveries with cesarean section used a combination of motherwort injection and oxytocin to prevent PPH among 51,312 included pregnancies. Compared to oxytocin alone, motherwort injection combined with oxytocin could reduce bleeding at postpartum 2 h and 24 h (2h: WMD = -40.95, 95 % CI -58.04 to -23.86; 24h: WMD = -54.80, 95 % CI -72.09 to -37.51) and reduced the half of PPH risk (RR = 0.49, 95 % CI 0.41 to 0.59). Similarly, in the PPH rat model, the combination therapy of motherwort injection and oxytocin further reduced PPH volume, shortened bleeding duration, and improved uterine histopathology, while upregulating the expression of OXTR and Cx43. Integrated network pharmacology and metabolomics analysis revealed that the primary synergistic mechanism of motherwort injection involves the MAPK signaling pathway. Further experimental evidence confirmed that the uterine contraction-enhancing effect of Leonurus japonicus injection is dependent on MEK/ERK activation, and its pharmacological action can be inhibited by the MEK inhibitor AZD6244. Cellular assays identified stachydrine as the principal bioactive component of motherwort injection, which elevates intracellular calcium levels in human uterine smooth muscle cells. Molecular docking, molecular dynamics simulations, and SPR analysis further identified MEK1 as a direct binding target of motherwort injection. CONCLUSION: Our study, from clinical phenomena to mechanism validation, demonstrates that the combined regimen of motherwort injection and oxytocin exhibits superior efficacy in preventing PPH compared to oxytocin monotherapy. A key mechanistic insight is the activation of the MAPK signaling pathway, which underpins the synergistic action of motherwort injection with oxytocin in enhancing uterine contraction. These findings highlight the therapeutic potential of integrating traditional Chinese medicine (motherwort injection) with Western medicine (oxytocin) for improved PPH management.
引用
- Chen C, Liu Q, Lu Y, et al. Motherwort synergized with oxytocin for postpartum hemorrhage prevention: Integrated clinical efficacy and mechanism exploration. Phytomedicine. 2025. PMID: 40527062. doi:10.1016/j.phymed.2025.156951
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。